Search

Your search keyword '"Epidermal growth factor -- Reports"' showing total 4 results
Start Over Descriptor "Epidermal growth factor -- Reports" Publisher pr newswire association llc
4 results on '"Epidermal growth factor -- Reports"'

1. Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Size to Grow by USD 6.75 Billion | Market Size, Completive Analysis, Industry Segments, Share and Forecast to 2026

Subjects
Johnson & Johnson Inc. -- Reports, Takeda Pharmaceutical Company Ltd. -- Reports, Amgen Inc. -- Reports, Pfizer Inc. -- Reports, Bristol-Myers Squibb Co. -- Reports, Boehringer Ingelheim GmbH -- Reports, Novartis AG -- Reports, Jiangsu Hansoh Pharmaceutical Group Company Ltd. -- Reports, F. Hoffmann-La Roche Ltd. -- Reports, AstraZeneca PLC -- Reports, Eli Lilly and Co. -- Reports, Biotechnology industry -- Industry forecasts, Health products industry -- Industry forecasts, Epidermal growth factor -- Reports, Industrial research -- Germany -- United Kingdom -- Switzerland -- China -- United States -- Canada -- Japan -- North America, Pharmaceutical industry -- Industry forecasts, Research and development, Business, News, opinion and commentary
Abstract

NEW YORK, March 31, 2022 /PRNewswire/ -- Thehttps://www.technavio.com/report/epidermal-growth-factor-receptor-egfr-inhibitors-market-industry-analysis?utm_source=prnewswire&utm_medium=pressrelease&utm_campaign=TNV3+%28T41%29_rep1_wk14_001_2022&utm_content=IRTNTR72701 value is set to grow by USD 6.75 billion, progressing at a CAGR of 8.6% from 2021 to 2026, as per the [...]

Published
2022

2. Patients Launch New Study to Shed Light on EGFR-Positive Lung Cancers

Subjects
Oncology, Experimental -- Reports, Lung cancer -- Reports, Cancer -- Research, Epidermal growth factor -- Reports, Business, News, opinion and commentary
Abstract

Scientists, physicians and patients collaborate to improve treatment for rare cancer SAN CARLOS, Calif., Nov. 15, 2018 /PRNewswire/ -- The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology and EGFR [...]

Published
2018

3. Real-world study shows sequencing of Gilotrif followed by osimertinib delivered a combined median time on treatment of 27.6 months in patients with EGFR mutation-positive NSCLC

Subjects
Boehringer Ingelheim Pharmaceuticals Inc. -- Reports, Cancer patients -- Care and treatment -- Reports, Lung cancer, Non-small cell -- Genetic aspects -- Care and treatment -- Reports, Epidermal growth factor -- Reports, Pharmaceutical industry -- Reports, Business, News, opinion and commentary, Gilotrif (Medication) -- Reports
Abstract

- GioTag is the first global, real-world study to evaluate sequencing of targeted treatments in patients with EGFR mutation-positive NSCLC developing the most common acquired treatment resistance mutation - Results [...]

Published
2018

4. Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK - Pipeline Review, H2 2017

Subjects
Tyrosine -- Reports, Phenols -- Reports, Endothelium -- Reports, Protein kinases -- Reports, Epidermal growth factor -- Reports, Business, News, opinion and commentary
Abstract

NEW YORK, July 18, 2017 /PRNewswire/ --Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine [...]

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results